Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 61)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
BCG vaccine |
Approved, Investigational |
Phase 3 |
|
|
|
Synonyms:
BACILLUS CALMETTE GUERIN VACCINE
BACILLUS CALMETTE GUÉRIN VACCINE
Bacillus Calmette–Guérin (BCG) vaccine
|
Bacillus calmette-guerin live antigen, unspecified substrain
BCG
BCG vaccine
|
|
2 |
|
Mitomycin |
Approved |
Phase 3 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
3 |
|
Vaccines |
|
Phase 3 |
|
|
|
4 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
5 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
6 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
7 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
8 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
9 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
10 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
11 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
12 |
|
Trastuzumab |
Approved, Investigational |
Phase 2 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
13 |
|
Hyaluronic acid |
Approved, Vet_approved |
Phase 2 |
|
9004-61-9 |
53477741 |
Synonyms:
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid
(2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate
|
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid
Hyaluronan
Hyaluronate
WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1
|
|
14 |
|
Lenalidomide |
Approved |
Phase 1, Phase 2 |
|
191732-72-6 |
216326 |
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CC-5013
CC-5013|CDC-501|Revlimid®
CDC 501
CDC-501
Celgene brand OF lenalidomide
IMID-1
|
IMiD3
IMiD3 CPD
Lenalidomida
LENALIDOMIDE
Revimid
Revlimid
SYP-1512
|
|
15 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
16 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
17 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
18 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
19 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
20 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
21 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
22 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
23 |
|
Iodine |
Approved, Investigational |
Phase 2 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
24 |
|
Cediranib |
Investigational |
Phase 1, Phase 2 |
|
288383-20-0 |
9933475 |
Synonyms:
4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE
AZD 2171
AZD 2171|AZD2171|ZD 2171
AZD-2171
|
CEDIRANIB
RECENTIN
ZD 2171
ZD-2171
|
|
25 |
|
Maleic acid |
Experimental, Investigational |
Phase 1, Phase 2 |
|
110-16-7, 110-17-8 |
444266 444972 |
Synonyms:
(2E)-2-Butenedioate
(2E)-2-Butenedioic acid
(2E)-But-2-enedioate
(2E)-But-2-enedioic acid
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(e)-2-Butenedioate
(e)-2-Butenedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-(e)-Butenedioate
2-(e)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
Allomaleate
Allomaleic acid
Boletate
Boletic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
e297
FC 33
Fumarate
Fumaric acid
Fumaricum acidum
Fumarsaeure
|
Fumarsäure
Furamag
H2Male
Hydrogen maleate
Kyselina maleinova
Lichenate
Lichenic acid
MAE
Mafusol
Maleate
MALEIC ACID
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
trans-1,2-Ethylenedicarboxylate
trans-1,2-Ethylenedicarboxylic acid
trans-2-Butenedioate
trans-2-Butenedioic acid
trans-But-2-enedioate
trans-But-2-enedioic acid
trans-Butenedioate
trans-Butenedioic acid
|
|
26 |
|
Cadexomer iodine |
Experimental |
Phase 2 |
|
94820-09-4 |
|
Synonyms:
|
27 |
|
Radiopharmaceuticals |
|
Phase 2 |
|
|
|
28 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
29 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
30 |
|
Fluorodeoxyglucose F18 |
|
Phase 2 |
|
|
|
31 |
|
Deoxyglucose |
|
Phase 2 |
|
|
|
32 |
|
Endothelial Growth Factors |
|
Phase 2 |
|
|
|
33 |
|
Mitogens |
|
Phase 2 |
|
|
|
34 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
35 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
36 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
37 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
38 |
|
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid |
|
Phase 2 |
|
|
|
39 |
|
Chelating Agents |
|
Phase 2 |
|
|
|
40 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
41 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
42 |
|
Trace Elements |
|
Phase 2 |
|
|
|
43 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
44 |
|
Anti-Infective Agents, Local |
|
Phase 2 |
|
|
|
45 |
|
Micronutrients |
|
Phase 2 |
|
|
|
46 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
47 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
48 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
49 |
|
Antibodies |
|
Phase 2 |
|
|
|
50 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 42)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder |
Completed |
NCT00002990 |
Phase 3 |
|
2 |
A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC |
Terminated |
NCT03335059 |
Phase 3 |
|
3 |
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy |
Completed |
NCT01811212 |
Phase 2 |
Cabozantinib S-malate |
4 |
Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements |
Completed |
NCT00559949 |
Phase 2 |
Selumetinib |
5 |
A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy |
Completed |
NCT00729157 |
Phase 2 |
|
6 |
Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage |
Completed |
NCT00416455 |
Phase 1, Phase 2 |
ferumoxtran-10 |
7 |
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma |
Completed |
NCT01367002 |
Phase 2 |
Carboplatin/Paclitaxel;Trastuzumab |
8 |
ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. A Phase II Marker Lesion. STUDY |
Completed |
NCT04661826 |
Phase 2 |
Oncofid-P-B |
9 |
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer |
Completed |
NCT01208051 |
Phase 1, Phase 2 |
Cediranib;Cediranib Maleate;Lenalidomide |
10 |
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial |
Recruiting |
NCT03753919 |
Phase 2 |
Durvalumab;Tremelimumab |
11 |
Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers |
Recruiting |
NCT04759911 |
Phase 2 |
Selpercatinib |
12 |
Treatment of a Long-lasting Radiolabeled Fibroblast Activation Protein Inhibitor 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer |
Recruiting |
NCT05410821 |
Phase 2 |
177Lu-DOTA-EB-FAPI 1 radionuclide therapy;177Lu-DOTA-EB-FAPI 2 radionuclide therapy;177Lu-DOTA-EB-FAPI 3 radionuclide therapy |
13 |
Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma |
Recruiting |
NCT04623801 |
Phase 2 |
|
14 |
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study |
Active, not recruiting |
NCT02973997 |
Phase 2 |
Lenvatinib;Lenvatinib Mesylate |
15 |
Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers |
Active, not recruiting |
NCT00381641 |
Phase 2 |
Sunitinib;Sunitinib Malate |
16 |
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers |
Active, not recruiting |
NCT02393690 |
Phase 2 |
Selumetinib |
17 |
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers |
Active, not recruiting |
NCT02152995 |
Phase 2 |
Trametinib |
18 |
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy |
Active, not recruiting |
NCT03914300 |
Phase 2 |
Cabozantinib S-malate |
19 |
A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer |
Terminated |
NCT03506048 |
Phase 2 |
Lenvatinib |
20 |
Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary |
Withdrawn |
NCT00003865 |
Phase 2 |
toremifene |
21 |
Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma |
Unknown status |
NCT02648399 |
|
|
22 |
Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial |
Unknown status |
NCT04411290 |
|
|
23 |
Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial |
Unknown status |
NCT04424485 |
|
|
24 |
A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma Suitable for Primary Hospitals |
Completed |
NCT05191927 |
|
|
25 |
Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma |
Completed |
NCT01150318 |
|
Administration of 131 iodine |
26 |
Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study |
Completed |
NCT01927887 |
|
Ferumoxytol |
27 |
Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy |
Completed |
NCT02768753 |
|
|
28 |
Proper Extent of Surgery for Papillary Microcarcinoma |
Completed |
NCT01648569 |
|
|
29 |
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others |
Completed |
NCT01392222 |
|
|
30 |
A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated |
Recruiting |
NCT02776969 |
|
|
31 |
Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer |
Recruiting |
NCT05575440 |
|
|
32 |
Radiofrequency Ablation Use in Thyroid Nodule |
Recruiting |
NCT05003856 |
Early Phase 1 |
|
33 |
Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma |
Recruiting |
NCT04129281 |
|
|
34 |
A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC) |
Recruiting |
NCT03808779 |
|
|
35 |
Active Surveillance of Papillary Thyroid Microcarcinoma |
Recruiting |
NCT02609685 |
|
|
36 |
RFA Treatment for Papillary Thyroid Microcarcinoma Cohort |
Recruiting |
NCT05189821 |
|
|
37 |
Genomic Predictors of Papillary Microcarcinoma Disease Progression |
Recruiting |
NCT02363595 |
|
|
38 |
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy |
Recruiting |
NCT03432299 |
|
|
39 |
Active Surveillance on Papillary Thyroid Microcarcinoma |
Active, not recruiting |
NCT02938702 |
|
|
40 |
What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development? |
Not yet recruiting |
NCT04376203 |
|
|
41 |
A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC) |
Suspended |
NCT03327636 |
|
|
42 |
Effectiveness of Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroid Surgery |
Terminated |
NCT03773120 |
|
|
|